YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. Pam Kaur | HSBC Pam Kaur, group chief financial officer of HSBC, plans to retire in 2027. After stepping do…
Kura Oncology, Inc.(NASDAQ:KURA) on Wednesday announced $50 million financing tied to advancing its menin-inhibition strategy. Launches Caspian Therapeutics With $50 Million Financing Kura said it is launching Caspian Therapeutics alongsid…
Kura Oncology, Inc. – $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneu…
An updated edition of the July 8, 2026, article. The global oncology market is undergoing significant transformation, driven by the rising burden of cancer, aging populations and rapid advances in medical science. According to the American…
Shares of DICK'S Sporting Goods, Inc. (DKS) plummeted 30.7% after the company reported second-quarter fiscal 2026 earnings of $3.53 per share, missing the Zacks Consensus Estimate of $3.78 per share. Kura Oncology, Inc.'s (KURA) shares jum…
Medical research scientist working with microscope in modern laboratory by snowing12 via Adobe Stock Kura Oncology (KURA) stock soared on Aug. 25 after a regulatory filing confirmed that CEO Troy Wilson has loaded up on company shares. The…
Troy Edward Wilson, the President, Chairman, and CEO of Kura Oncology, Inc. (NASDAQ:KURA), purchased ~100,000 shares of common stock on August 24, 2026. SEC Form 4 filing. Company snapshot Sector: Healthcare Industry: Biotechnology Headqua…
Check out the companies making the biggest moves midday: Dick's Sporting Goods — Shares plunged more than 27% following a revenue disappointment out of the sports equipment retailer, which cited a "challenging" market for footwear. Dick's…
Medical research ©rawpixel Kura Oncology Inc. (NASDAQ:KURA) shares climbed 11.0% in pre-market trading on Tuesday after President and Chief Executive Officer Troy Edward Wilson purchased approximately $1.24 million worth of the company's s…
Check out the companies making headlines before the bell: Dick's Sporting Goods — Shares plunged more than 12% following a revenue disappointment out of the sports equipment retailer, which cited a "challenging" market for footwear. Dick's…
Kura Oncology, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list. TheFly reported on June 12 that Guggenheim an…
Kura Oncology, Inc. – 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – High rates of MRD n…
SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on Jun…
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients – – Clinica…
Kura Oncology, Inc. – 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax…
(RTTNews) - Kura Oncology, Inc. (KURA), a biopharmaceutical company focused on precision medicine for cancer treatment, on Tuesday announced positive results from a phase 1 trial of its next-generation farnesyl transferase inhibitor (FTI),…
Kura Oncology, Inc. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1…
U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Wednesday. Shares of QuickLogic Corp(NASDAQ:QUIK) fell in pre-market trading after the company reported worse-than-expected first-quarter financi…
This article first appeared on GuruFocus. Net Product Revenue: $5.8 million from KOMZIFTI sales in Q1 2026. Collaboration Revenue: $12.5 million from Kyowa Kirin partnership in Q1 2026. Research and Development Expenses: $65.3 million in Q…
Key Points Interested in Kura Oncology, Inc.? Here are five stocks we like better. Kura Oncology reported its first full quarter of KOMZIFTI sales at $5.8 million, with management saying the launch is off to a strong start thanks to physic…
The following companies are expected to report earnings after hours on 05/12/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Franco-Nevada Corporation (FNV)is reporting for the quarter ending March 31, 2026…
Kura Oncology, Inc. – Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses…
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable responses with median duration…
Celldex Therapeutics (CLDX) came out with a quarterly loss of $1.18 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.…
SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Ban…
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announ…
Shares of Kura Oncology KURA rose 8% after the company announced encouraging preliminary data from the ongoing FIT-001 study evaluating darlifarnib in combination with cabozantinib. The analysis focused on patients with clear cell renal ce…
Kura Oncology (KURA) shares rallied 8.3% in the last trading session to close at $9.68. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.1…
Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Health care stocks climbed Friday afternoon, with the NYSE Health Care Index rising 1.7% and the Sta PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrink…
Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST…
SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on Ap…
Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, region…
Kura Oncology logo Key Points Komzifti launched with early commercial traction—generating $2.1 million in net product revenue in the final weeks of 2025—and achieved rapid market access (payers covering ~84% of private lives and ~90% of in…